CYTK (Cytokinetics) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


CYTK Cytokinetics Inc CYTK
51 GF Score
Price $82.02
GF Value $248.69
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Cytokinetics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Cytokinetics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

CYTK vs ARWR, BMRN, PRAX: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Cytokinetics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytokinetics Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Margin of Safety % (DCF Earnings Based) falls into.


CYTK
51GF Score
Cytokinetics Inc CYTK
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cytokinetics (CYTK) Overvalued in 2026?

Based on GuruFocus' analysis, Cytokinetics stock appears to be undervalued. The current stock price of $82.02 is trading 67% below its estimated GF Value™ of $248.69. GuruFocus considers Cytokinetics to be Possible Value Trap.

Key valuation signals for CYTK:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $248.69 vs. price of $82.02 (67% below fair value)
  • GF Score™: 51/100 with 7 warning signs

No single metric tells the full story. See the CYTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cytokinetics Business Description

Other Exchanges 1CYTK:ItalyKK3A:Germany
Address 350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
51GF Score

Get the complete analysis for CYTK

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$82.02
Price
$248.69
GF Value